行情

COLL

COLL

Collegium Pharm
NASDAQ

实时行情|Nasdaq Last Sale

16.13
+0.48
+3.07%
盘后: 16.20 +0.07 +0.43% 17:04 04/03 EDT
开盘
15.55
昨收
15.65
最高
16.18
最低
15.34
成交量
31.39万
成交额
--
52周最高
25.59
52周最低
10.01
市值
5.49亿
市盈率(TTM)
-23.7276
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测COLL价格均价为33.57,最高价位38.00,最低价为24.00。

EPS

COLL 新闻

更多
  • 特朗普称如果需要保护石油产业 他会使用关税
  • 新浪美股 · 1小时前
  • 特朗普称使用国防生产法是为了“报复”
  • 新浪美股 · 1小时前
  • 毕马威首席经济学家:冠状病毒导致的失业比大衰退时期更糟
  • 新浪美股 · 1小时前
  • 欧佩克+会议推迟 沙特与俄罗斯紧张局势升级 周一油价料将暴跌
  • 新浪美股 · 3小时前

所属板块

制药
-0.14%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

COLL 简况

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
展开

微牛提供Collegium Pharmaceutical Inc(NASDAQ-COLL)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的COLL股票新闻,以帮助您做出投资决策。